UNSPSC 51263009: Prazosin hydrochloride

This classification denotes an antihypertensive agent and alpha-adrenergic blocking agent with the molecular formula C19H21N5O4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier X0Z7454B90, chemically known as 4-(4-amino-6,7-dimethoxyquinazolin-2-yl)piperazinyl 2-furyl ketone but more generally known as prazosin hydrochloride, which bears US NIH Compound Identifier 4893. European Medicines Agency schedules Prazosin hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04013MIG.

UNSPSC 51263009 Prazosin hydrochloride is a Commodity code that maps to pharmaceutical procurement by state and local health agencies, though the recent opportunities tagged to this code show a mismatch with the specific drug name. Seminole County, Florida and the Texas Health and Human Services Commission are the issuing bodies represented in recent activity, both health agencies managing prescription and medication inventories. Seminole County is procuring naloxone and drug deactivation systems through competitive bidding, while Texas HHS is gathering market intelligence on direct-to-manufacturer prescription fulfillment models. State health departments and county health authorities appear to be the primary issuing bodies using this code for pharmaceutical and medication procurement.

Recent activity concentrates in Florida and Texas. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, response due July 26, 2023, on a fixed-fee basis with a two-year initial term and one-year renewal option. Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program that would establish direct contracting relationships between state pharmacy benefit programs and manufacturers, bypassing traditional pharmacy benefit managers and group purchasing organizations. The Texas RFI is exploratory in nature and will inform subsequent formal procurement; no award value or budget range is stated at this stage.